Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease

Phosphodiesterase 10A (PDE10A), the enzyme which catalyzes hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), is located almost exclusively in striatal γ-amino-butyric acid (GABA)ergic medium spiny neurons (MSNs). Since dopaminergic deficiency in Parkinson...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmacology 2021-11, Vol.910, p.174460-174460, Article 174460
Hauptverfasser: Lenda, Tomasz, Ossowska, Krystyna, Berghauzen-Maciejewska, Klemencja, Matłoka, Mikołaj, Pieczykolan, Jerzy, Wieczorek, Maciej, Konieczny, Jolanta
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 174460
container_issue
container_start_page 174460
container_title European journal of pharmacology
container_volume 910
creator Lenda, Tomasz
Ossowska, Krystyna
Berghauzen-Maciejewska, Klemencja
Matłoka, Mikołaj
Pieczykolan, Jerzy
Wieczorek, Maciej
Konieczny, Jolanta
description Phosphodiesterase 10A (PDE10A), the enzyme which catalyzes hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), is located almost exclusively in striatal γ-amino-butyric acid (GABA)ergic medium spiny neurons (MSNs). Since dopaminergic deficiency in Parkinson's disease (PD) leads to functional imbalance of striatal direct and indirect output pathways formed by MSNs, PDE10A seems to be of special interest as a potential therapeutic target in PD. The aim of the present study was to examine the influence of 7-{5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl}-2-phenylimidazo[1,2-a]pyrimidine (CPL500036), a novel selective inhibitor of PDE10A, on sensorimotor deficits and therapeutic effects of L-3,4-dihydroxyphenylalanine (L-DOPA) in hemiparkinsonian rats. Animals were unilaterally lesioned with 6-hydroxydopamine, and their sensorimotor deficits were examined in the stepping, cylinder, vibrissae and catalepsy tests. CPL500036 (0.1 and 0.3 mg/kg) was administered either acutely or chronically (2 weeks), alone or in combination with L-DOPA/benserazide (6 mg/kg/6 mg/kg). Acute treatment with CPL500036 reversed the lesion-induced impairments of contralateral forelimb use in the stepping and cylinder tests but did not influence deficits in the vibrissae test and the lesion-induced catalepsy. Moreover, CPL500036 did not diminish the therapeutic effects produced by acute and chronic treatment with L-DOPA in these tests. The present study suggests a potential use of CPL500036 as a co-treatment to L-DOPA in PD therapy. •Unilateral 6-OHDA lesion induced sensorimotor impairment and catalepsy in rats.•CPL500036, a PDE10A inhibitor, reduced sensorimotor deficits in 6-OHDA-lesioned rats.•Acute and chronic CPL500036 did not reduce effects of L-DOPA in sensorimotor tests.•Chronic CPL500036 treatment did not decrease L-DOPA-induced contralateral rotation.
doi_str_mv 10.1016/j.ejphar.2021.174460
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2568609257</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299921006142</els_id><sourcerecordid>2568609257</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-f7c104fb23f59afac7ccf662a250ce98d1f07123967bf3436600c5b8cb63eb9b3</originalsourceid><addsrcrecordid>eNp9kcFu3CAURVHVKJmm-YOqYtcu4ukD29hsKo1GbRpppGbRrhHGDw0TD7jgGan_kQ8ulpMus0BIcO67cC8hHxisGTDx5bDGw7jXcc2BszVrqkrAG7JibSMLaBh_S1YArCq4lPKKvEvpAAC15PUluSozLJtarMjTxk9u1PHR-RS8074Y3CNStBbNlGiwdPuwq7OyFLdUUx_OONCEQ751Z6TO713nphBnctyHlFfvME0YdULKYHObGTrtkZ68G_R8PtCoJ3oMfZ6UVQ8v5p8S7V3CrHtPLqweEt4879fk9_dvv7Y_it3Pu_vtZleYCtqpsI1hUNmOl7aW2mrTGGOF4JrXYFC2PbNzEKUUTWfLqhQCwNRdazpRYie78pp8XuaOMfw55Vero0sGh0F7DKekeC1aATmyJqPVgpoYUopo1RjdUce_ioGa-1AHtfSh5j7U0keWfXx2OHVH7P-LXgrIwNcFwPzPs8OoknHoDfYu5oxVH9zrDv8ACgWewg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2568609257</pqid></control><display><type>article</type><title>Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Lenda, Tomasz ; Ossowska, Krystyna ; Berghauzen-Maciejewska, Klemencja ; Matłoka, Mikołaj ; Pieczykolan, Jerzy ; Wieczorek, Maciej ; Konieczny, Jolanta</creator><creatorcontrib>Lenda, Tomasz ; Ossowska, Krystyna ; Berghauzen-Maciejewska, Klemencja ; Matłoka, Mikołaj ; Pieczykolan, Jerzy ; Wieczorek, Maciej ; Konieczny, Jolanta</creatorcontrib><description>Phosphodiesterase 10A (PDE10A), the enzyme which catalyzes hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), is located almost exclusively in striatal γ-amino-butyric acid (GABA)ergic medium spiny neurons (MSNs). Since dopaminergic deficiency in Parkinson's disease (PD) leads to functional imbalance of striatal direct and indirect output pathways formed by MSNs, PDE10A seems to be of special interest as a potential therapeutic target in PD. The aim of the present study was to examine the influence of 7-{5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl}-2-phenylimidazo[1,2-a]pyrimidine (CPL500036), a novel selective inhibitor of PDE10A, on sensorimotor deficits and therapeutic effects of L-3,4-dihydroxyphenylalanine (L-DOPA) in hemiparkinsonian rats. Animals were unilaterally lesioned with 6-hydroxydopamine, and their sensorimotor deficits were examined in the stepping, cylinder, vibrissae and catalepsy tests. CPL500036 (0.1 and 0.3 mg/kg) was administered either acutely or chronically (2 weeks), alone or in combination with L-DOPA/benserazide (6 mg/kg/6 mg/kg). Acute treatment with CPL500036 reversed the lesion-induced impairments of contralateral forelimb use in the stepping and cylinder tests but did not influence deficits in the vibrissae test and the lesion-induced catalepsy. Moreover, CPL500036 did not diminish the therapeutic effects produced by acute and chronic treatment with L-DOPA in these tests. The present study suggests a potential use of CPL500036 as a co-treatment to L-DOPA in PD therapy. •Unilateral 6-OHDA lesion induced sensorimotor impairment and catalepsy in rats.•CPL500036, a PDE10A inhibitor, reduced sensorimotor deficits in 6-OHDA-lesioned rats.•Acute and chronic CPL500036 did not reduce effects of L-DOPA in sensorimotor tests.•Chronic CPL500036 treatment did not decrease L-DOPA-induced contralateral rotation.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/j.ejphar.2021.174460</identifier><identifier>PMID: 34469756</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Antiparkinson Agents - pharmacology ; Antiparkinson Agents - therapeutic use ; Disease Models, Animal ; GABAergic Neurons - drug effects ; Humans ; L-DOPA ; Levodopa - pharmacology ; Levodopa - therapeutic use ; Male ; Oxidopamine - administration &amp; dosage ; Oxidopamine - toxicity ; Parkinson Disease, Secondary - chemically induced ; Parkinson Disease, Secondary - diagnosis ; Parkinson Disease, Secondary - drug therapy ; Parkinson Disease, Secondary - pathology ; Parkinson's disease ; PDE10A inhibitor ; Phosphodiesterase Inhibitors - pharmacology ; Phosphodiesterase Inhibitors - therapeutic use ; Phosphoric Diester Hydrolases - metabolism ; Rats ; Rotation ; Sensorimotor deficits ; Severity of Illness Index ; Unilateral rat model</subject><ispartof>European journal of pharmacology, 2021-11, Vol.910, p.174460-174460, Article 174460</ispartof><rights>2021 The Authors</rights><rights>Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-f7c104fb23f59afac7ccf662a250ce98d1f07123967bf3436600c5b8cb63eb9b3</citedby><cites>FETCH-LOGICAL-c408t-f7c104fb23f59afac7ccf662a250ce98d1f07123967bf3436600c5b8cb63eb9b3</cites><orcidid>0000-0002-4800-6511 ; 0000-0001-5011-1620</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejphar.2021.174460$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34469756$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lenda, Tomasz</creatorcontrib><creatorcontrib>Ossowska, Krystyna</creatorcontrib><creatorcontrib>Berghauzen-Maciejewska, Klemencja</creatorcontrib><creatorcontrib>Matłoka, Mikołaj</creatorcontrib><creatorcontrib>Pieczykolan, Jerzy</creatorcontrib><creatorcontrib>Wieczorek, Maciej</creatorcontrib><creatorcontrib>Konieczny, Jolanta</creatorcontrib><title>Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Phosphodiesterase 10A (PDE10A), the enzyme which catalyzes hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), is located almost exclusively in striatal γ-amino-butyric acid (GABA)ergic medium spiny neurons (MSNs). Since dopaminergic deficiency in Parkinson's disease (PD) leads to functional imbalance of striatal direct and indirect output pathways formed by MSNs, PDE10A seems to be of special interest as a potential therapeutic target in PD. The aim of the present study was to examine the influence of 7-{5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl}-2-phenylimidazo[1,2-a]pyrimidine (CPL500036), a novel selective inhibitor of PDE10A, on sensorimotor deficits and therapeutic effects of L-3,4-dihydroxyphenylalanine (L-DOPA) in hemiparkinsonian rats. Animals were unilaterally lesioned with 6-hydroxydopamine, and their sensorimotor deficits were examined in the stepping, cylinder, vibrissae and catalepsy tests. CPL500036 (0.1 and 0.3 mg/kg) was administered either acutely or chronically (2 weeks), alone or in combination with L-DOPA/benserazide (6 mg/kg/6 mg/kg). Acute treatment with CPL500036 reversed the lesion-induced impairments of contralateral forelimb use in the stepping and cylinder tests but did not influence deficits in the vibrissae test and the lesion-induced catalepsy. Moreover, CPL500036 did not diminish the therapeutic effects produced by acute and chronic treatment with L-DOPA in these tests. The present study suggests a potential use of CPL500036 as a co-treatment to L-DOPA in PD therapy. •Unilateral 6-OHDA lesion induced sensorimotor impairment and catalepsy in rats.•CPL500036, a PDE10A inhibitor, reduced sensorimotor deficits in 6-OHDA-lesioned rats.•Acute and chronic CPL500036 did not reduce effects of L-DOPA in sensorimotor tests.•Chronic CPL500036 treatment did not decrease L-DOPA-induced contralateral rotation.</description><subject>Animals</subject><subject>Antiparkinson Agents - pharmacology</subject><subject>Antiparkinson Agents - therapeutic use</subject><subject>Disease Models, Animal</subject><subject>GABAergic Neurons - drug effects</subject><subject>Humans</subject><subject>L-DOPA</subject><subject>Levodopa - pharmacology</subject><subject>Levodopa - therapeutic use</subject><subject>Male</subject><subject>Oxidopamine - administration &amp; dosage</subject><subject>Oxidopamine - toxicity</subject><subject>Parkinson Disease, Secondary - chemically induced</subject><subject>Parkinson Disease, Secondary - diagnosis</subject><subject>Parkinson Disease, Secondary - drug therapy</subject><subject>Parkinson Disease, Secondary - pathology</subject><subject>Parkinson's disease</subject><subject>PDE10A inhibitor</subject><subject>Phosphodiesterase Inhibitors - pharmacology</subject><subject>Phosphodiesterase Inhibitors - therapeutic use</subject><subject>Phosphoric Diester Hydrolases - metabolism</subject><subject>Rats</subject><subject>Rotation</subject><subject>Sensorimotor deficits</subject><subject>Severity of Illness Index</subject><subject>Unilateral rat model</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFu3CAURVHVKJmm-YOqYtcu4ukD29hsKo1GbRpppGbRrhHGDw0TD7jgGan_kQ8ulpMus0BIcO67cC8hHxisGTDx5bDGw7jXcc2BszVrqkrAG7JibSMLaBh_S1YArCq4lPKKvEvpAAC15PUluSozLJtarMjTxk9u1PHR-RS8074Y3CNStBbNlGiwdPuwq7OyFLdUUx_OONCEQ751Z6TO713nphBnctyHlFfvME0YdULKYHObGTrtkZ68G_R8PtCoJ3oMfZ6UVQ8v5p8S7V3CrHtPLqweEt4879fk9_dvv7Y_it3Pu_vtZleYCtqpsI1hUNmOl7aW2mrTGGOF4JrXYFC2PbNzEKUUTWfLqhQCwNRdazpRYie78pp8XuaOMfw55Vero0sGh0F7DKekeC1aATmyJqPVgpoYUopo1RjdUce_ioGa-1AHtfSh5j7U0keWfXx2OHVH7P-LXgrIwNcFwPzPs8OoknHoDfYu5oxVH9zrDv8ACgWewg</recordid><startdate>20211105</startdate><enddate>20211105</enddate><creator>Lenda, Tomasz</creator><creator>Ossowska, Krystyna</creator><creator>Berghauzen-Maciejewska, Klemencja</creator><creator>Matłoka, Mikołaj</creator><creator>Pieczykolan, Jerzy</creator><creator>Wieczorek, Maciej</creator><creator>Konieczny, Jolanta</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4800-6511</orcidid><orcidid>https://orcid.org/0000-0001-5011-1620</orcidid></search><sort><creationdate>20211105</creationdate><title>Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease</title><author>Lenda, Tomasz ; Ossowska, Krystyna ; Berghauzen-Maciejewska, Klemencja ; Matłoka, Mikołaj ; Pieczykolan, Jerzy ; Wieczorek, Maciej ; Konieczny, Jolanta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-f7c104fb23f59afac7ccf662a250ce98d1f07123967bf3436600c5b8cb63eb9b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Antiparkinson Agents - pharmacology</topic><topic>Antiparkinson Agents - therapeutic use</topic><topic>Disease Models, Animal</topic><topic>GABAergic Neurons - drug effects</topic><topic>Humans</topic><topic>L-DOPA</topic><topic>Levodopa - pharmacology</topic><topic>Levodopa - therapeutic use</topic><topic>Male</topic><topic>Oxidopamine - administration &amp; dosage</topic><topic>Oxidopamine - toxicity</topic><topic>Parkinson Disease, Secondary - chemically induced</topic><topic>Parkinson Disease, Secondary - diagnosis</topic><topic>Parkinson Disease, Secondary - drug therapy</topic><topic>Parkinson Disease, Secondary - pathology</topic><topic>Parkinson's disease</topic><topic>PDE10A inhibitor</topic><topic>Phosphodiesterase Inhibitors - pharmacology</topic><topic>Phosphodiesterase Inhibitors - therapeutic use</topic><topic>Phosphoric Diester Hydrolases - metabolism</topic><topic>Rats</topic><topic>Rotation</topic><topic>Sensorimotor deficits</topic><topic>Severity of Illness Index</topic><topic>Unilateral rat model</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lenda, Tomasz</creatorcontrib><creatorcontrib>Ossowska, Krystyna</creatorcontrib><creatorcontrib>Berghauzen-Maciejewska, Klemencja</creatorcontrib><creatorcontrib>Matłoka, Mikołaj</creatorcontrib><creatorcontrib>Pieczykolan, Jerzy</creatorcontrib><creatorcontrib>Wieczorek, Maciej</creatorcontrib><creatorcontrib>Konieczny, Jolanta</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lenda, Tomasz</au><au>Ossowska, Krystyna</au><au>Berghauzen-Maciejewska, Klemencja</au><au>Matłoka, Mikołaj</au><au>Pieczykolan, Jerzy</au><au>Wieczorek, Maciej</au><au>Konieczny, Jolanta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2021-11-05</date><risdate>2021</risdate><volume>910</volume><spage>174460</spage><epage>174460</epage><pages>174460-174460</pages><artnum>174460</artnum><issn>0014-2999</issn><eissn>1879-0712</eissn><abstract>Phosphodiesterase 10A (PDE10A), the enzyme which catalyzes hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), is located almost exclusively in striatal γ-amino-butyric acid (GABA)ergic medium spiny neurons (MSNs). Since dopaminergic deficiency in Parkinson's disease (PD) leads to functional imbalance of striatal direct and indirect output pathways formed by MSNs, PDE10A seems to be of special interest as a potential therapeutic target in PD. The aim of the present study was to examine the influence of 7-{5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl}-2-phenylimidazo[1,2-a]pyrimidine (CPL500036), a novel selective inhibitor of PDE10A, on sensorimotor deficits and therapeutic effects of L-3,4-dihydroxyphenylalanine (L-DOPA) in hemiparkinsonian rats. Animals were unilaterally lesioned with 6-hydroxydopamine, and their sensorimotor deficits were examined in the stepping, cylinder, vibrissae and catalepsy tests. CPL500036 (0.1 and 0.3 mg/kg) was administered either acutely or chronically (2 weeks), alone or in combination with L-DOPA/benserazide (6 mg/kg/6 mg/kg). Acute treatment with CPL500036 reversed the lesion-induced impairments of contralateral forelimb use in the stepping and cylinder tests but did not influence deficits in the vibrissae test and the lesion-induced catalepsy. Moreover, CPL500036 did not diminish the therapeutic effects produced by acute and chronic treatment with L-DOPA in these tests. The present study suggests a potential use of CPL500036 as a co-treatment to L-DOPA in PD therapy. •Unilateral 6-OHDA lesion induced sensorimotor impairment and catalepsy in rats.•CPL500036, a PDE10A inhibitor, reduced sensorimotor deficits in 6-OHDA-lesioned rats.•Acute and chronic CPL500036 did not reduce effects of L-DOPA in sensorimotor tests.•Chronic CPL500036 treatment did not decrease L-DOPA-induced contralateral rotation.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>34469756</pmid><doi>10.1016/j.ejphar.2021.174460</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-4800-6511</orcidid><orcidid>https://orcid.org/0000-0001-5011-1620</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0014-2999
ispartof European journal of pharmacology, 2021-11, Vol.910, p.174460-174460, Article 174460
issn 0014-2999
1879-0712
language eng
recordid cdi_proquest_miscellaneous_2568609257
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Animals
Antiparkinson Agents - pharmacology
Antiparkinson Agents - therapeutic use
Disease Models, Animal
GABAergic Neurons - drug effects
Humans
L-DOPA
Levodopa - pharmacology
Levodopa - therapeutic use
Male
Oxidopamine - administration & dosage
Oxidopamine - toxicity
Parkinson Disease, Secondary - chemically induced
Parkinson Disease, Secondary - diagnosis
Parkinson Disease, Secondary - drug therapy
Parkinson Disease, Secondary - pathology
Parkinson's disease
PDE10A inhibitor
Phosphodiesterase Inhibitors - pharmacology
Phosphodiesterase Inhibitors - therapeutic use
Phosphoric Diester Hydrolases - metabolism
Rats
Rotation
Sensorimotor deficits
Severity of Illness Index
Unilateral rat model
title Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T07%3A07%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiparkinsonian-like%20effects%20of%20CPL500036,%20a%20novel%20selective%20inhibitor%20of%20phosphodiesterase%2010A,%20in%20the%20unilateral%20rat%20model%20of%20Parkinson's%20disease&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Lenda,%20Tomasz&rft.date=2021-11-05&rft.volume=910&rft.spage=174460&rft.epage=174460&rft.pages=174460-174460&rft.artnum=174460&rft.issn=0014-2999&rft.eissn=1879-0712&rft_id=info:doi/10.1016/j.ejphar.2021.174460&rft_dat=%3Cproquest_cross%3E2568609257%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2568609257&rft_id=info:pmid/34469756&rft_els_id=S0014299921006142&rfr_iscdi=true